Skip to main content
Premium Trial:

Request an Annual Quote

EXCLUSIVE: DiaDexus and Beyond Genomics Close to Announcing Collaboration

For an updated version of this story please click here.

 

NEW YORK, Feb. 6 - Systems biology company Beyond Genomics is close to striking a research collaboration with DiaDexus, one person from each company told GenomeWeb.

 

It would be the second partnership for startup Beyond Genomics. The company's maiden deal was inked last May with Elan Pharmaceuticals to apply its systems biology techniques for Alzheimer's research.

 

It was not immediately clear whether this new collaboration would be like the Elan deal.

 

A source close to one of the companies said that DiaDexus, which uses genomic sequence data to develop diagnostic and therapeutic targets with a special focus on cancer, is unable to comment because it is in a silent period that precedes an IPO.

 

Officials from Beyond Genomics would not return telephone calls seeking comment.

Beyond Genomics aims to increase the current level of throughput achieved by existing technologies and combine this capability with the ability to generate genomics, proteomics, and metabolite data.


In its deal with Elan, Beyond Genomics got a $5 million equity investment in exchange for a two-year commitment to help the pharma giant find biomarkers and drug targets for Alzheimer's disease.


"In addition to providing clinical expertise and support for the program, Elan will grant the joint venture a non-exclusive license to an important animal model, a mouse strain which develops many of the features of the human disease," Stephen Ober, president of Cambridge, Mass.-based Beyond Genomics, said in May.

At the time, Elan Pharmaceuticals said it believed Beyond Genomics' technology could potentially help to uncover new proteins at play in Alzheimer's.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.